0 63

Cited 0 times in

Treatment efficacy analysis of preoperative neoadjuvant chemoradiation therapy in borderline resectable pancreatic cancer

Other Titles
 경계절제가능군 췌장암 환자에서 수술 전 동시항암화학방사선요법의 유용성 평가 
Authors
 조인래 
Issue Date
2013
Description
Dept. of Medicine/석사
Abstract
Background : Borderline resectable pancreatic cancer (BRPC) is defined as the presence of tumor extension to the adjacent visceral arteries (SMA, celiac axis, hepatic artery) or veins (SMV, PV) without distant metastasis. Although, margin-negative resection is the only modality to cure pancreatic cancer, BRPC patients have the risk of incomplete curative resection. In addition, surgical outcome of BRPC is thought be poor because of the increased complexity of surgery and advanced nature of the tumor even though margin-negative resection was done successfully. Nowadays, several approaches with neoadjuvant chemoradiation therapy for BRPC patients were being developed. The aim of this study is to evaluate whether neoadjuvant chemoradiation therapy in BRPC patients could improve survival.Patient and Method : Total 338 pancreatic cancer patients were treated with operation in a single tertiary medical center in Korea between January 2002 and December 2011. Of these, 51 patients (15.1%) had BRPC. 30 (8.9%) patients underwent neoadjuvant chemoradiation therapy prior to surgery (CCRT (+) group) and 21 (6.2%) patients underwent surgery without any neoadjuvant treatment (CCRT (−) group). Patient outcomes of two groups were evaluated retrospectively. Result : Overall survival of all patients was 26.6 months (median). Overall survival in the two groups was significantly different. (45.0 months in CCRT (+) group and 23.5 months in CCRT (-) group; p=0.045). CCRT (+) group showed lower recurrent rate (50.0% vs. 81.0%; p=0.024) and longer median disease-free survival period (21.0 months vs. 10.6 months; p=0.004) than CCRT (-) group. Conclusion : Neoadjuvant chemoradiation therapy seems to show superior patient outcomes in BRPC. Further clinical trials might be needed about the chemotherapeutic agent and the modality of radiotherapy.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/134525
Appears in Collections:
2. Thesis / Dissertation (학위논문) > 1. College of Medicine (의과대학) > Master's Degree (석사)
사서에게 알리기
  feedback
Full Text
https://ymlib.yonsei.ac.kr/catalog/search/book-detail/?cid=CAT000000129947
Files in This Item:
제한공개 원문입니다.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse